

March 25, 2026
J-Pharma Co., Ltd.

Notice of Listing on the Tokyo Stock Exchange Growth Market

J-Pharma Co., Ltd. (Head Office: Minato-ku, Tokyo; President and CEO: Masuhiro Yoshitake; Stock Code: 520A) was listed on the Tokyo Stock Exchange Growth Market on March 25, 2026.

We are pleased to announce this milestone and would like to express our sincere gratitude to all of our stakeholders for their continued support and encouragement since our founding.



The Company leverages its proprietary research platform targeting SLC transporters as a strength to create innovative new medicines in disease areas with high unmet medical needs. Under a development strategy with a global perspective, we are steadily advancing our research and development activities, aiming to achieve sustainable corporate growth and enhance social value.

As a leading company in the development of LAT1 inhibitors, we have achieved the following progress across our two key development programs:

- **LAT1 inhibitor nanvuranlat:** A global Phase III clinical trial for the second-line treatment of biliary tract cancer has been initiated.
- **LAT1 inhibitor JPH034:** The U.S. Food and Drug Administration (FDA) cleared its safety review of the Investigational New Drug (IND) application for multiple sclerosis on February 12, 2026 (U.S. time), and a Phase I clinical trial was initiated on March 22, 2026 in the United States. The development of JPH034 has been supported by the Drug Discovery Venture Ecosystem Program of the Japan Agency for Medical Research and Development (AMED) (research project title: “A Novel LAT1 Inhibitor for Multiple Sclerosis”).

About J-Pharma Co., Ltd.

Our corporate philosophy is "By pursuing new possibilities for SLC transporters and developing innovative new drugs that address unmet medical needs, we will contribute to supporting people around the world to maintain good health and hope." Based on this philosophy, we will work to create innovative pharmaceuticals to achieve sustainable corporate growth and increase social value.

For more information, please visit: <https://www.j-pharma.com/en/>

Inquiries:

J-Pharma Co., Ltd.

Planning Department

TEL: +81-3-6432-4270

<https://www.j-pharma.com/en/contact>

Important Notice

This press release does not constitute a part of any offering of securities. This press release has been prepared for the purpose of publicly announcing the approval of the listing of the Company's shares on the Tokyo Stock Exchange Growth Market and has not been prepared for the purpose of soliciting investments, whether within or outside Japan. Any final decision regarding investment should be made at the discretion of investors after carefully reviewing the prospectus for the issuance of new shares and the secondary offering of shares (including any amendments thereto) prepared by the Company. This press release does not constitute an

offer to sell or the solicitation of an offer to buy securities in the United States. The securities referred to herein may not be offered or sold in the United States absent registration under the U.S. Securities Act of 1933, or an applicable exemption from the registration requirements thereof. No offering of securities will be made in the United States in connection with this matter.